Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy
Fig 10
(A) Delivery profiles of irinotecan, oxaliplatin, 5-fluorouracil and glucose flushes as administered in the OPTILIV clinical trial. (B) Schematic of the Mélodie infusion pump (Axoncable, Montmirail, France) used in the OPTILIV study for hepatic artery infusion [20].